SCHEMBL10003837

SCHEMBL10003837

CCOC(=O)c1c(OCC(F)(F)F)c2nc(-c3ccccc3)c(CC)nc2n1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRA2 P47869 5/20 0.43
▸ GABRB2 P47870 5/20 0.43
▸ CYP1A2 P05177 4/20 0.43
▸ CYP2C9 P11712 4/20 0.43
▸ CYP2C19 P33261 4/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ ADORA3 P0DMS8 6/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.39
▸ HPGD P15428 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003449 0.92 GABRA2 (0.44) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10004308 0.90 CYP1A2 (0.44) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10003232 0.90 CACNA1G (0.35) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10004349 0.84 HTT (0.44) ADORA3SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL10004315 0.83 NPC1 (0.42) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10003156 0.83 KDM4E (0.41) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10003341 0.83 GRIA2 (0.38) GABRA2GABRB2CYP1A2MEN1CYP3A4
SCHEMBL10003557 0.82 CYP1A2 (0.44) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10002988 0.82 GABRA2 (0.50) GABRA2GABRB2CYP1A2CYP2C9CYP2C19
SCHEMBL10003011 0.80 HCRTR1 (0.36) GABRA2GABRB2CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GABRA2 2197/4885GABRB2 1779/4885CYP1A2 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback